Kyle Bass Claims Pink Sheet Article As Prior Art In Juxtapid Patent Challenge
This article was originally published in The Pink Sheet Daily
University of Pennsylvania argues neither 2004 article nor slide presentation it describes constitutes prior art that would invalidate method of use claims.
You may also be interested in...
Aegerion’s Juxtapid Needs Long-term Post-Market Cohort Study After FDA Nod
Sponsor will institute a registry to monitor patients taking the LDL cholesterol-lowering drug for homozygous familial hypercholesterolemia for 10 years, as part of an approval that is a likely template for Genzyme’s Kynamro.
False Claims Act Liability: Defendant’s Belief Claims Were False Matters, Supreme Court Finds
In unanimous decision, court backs whistleblowers’ fraud theory that SuperValu and Safeway defrauded Medicare and Medicaid by reporting higher retail prices than their discounted prices. BIO, AdvaMed and MIWG submitted amicus brief in support of the retail pharmacies.
DOJ Enforcement: Talking With US FDA Is Not Enough To Get Credit For Self-Disclosure
Remediation of a problem with FDA is one factor the DOJ considers in assessing whether a company gets credit for self-disclosure of misconduct prior to a criminal investigation, but it wants companies to come directly to the department to divulge wrongdoing.